TUMETABO

Glycolytic contribution to cancer growth and metastasis

 Coordinatore UNIVERSITE CATHOLIQUE DE LOUVAIN 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Belgium [BE]
 Totale costo 1˙493˙320 €
 EC contributo 1˙493˙320 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2009-StG
 Funding Scheme ERC-SG
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-12-01   -   2014-11-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITE CATHOLIQUE DE LOUVAIN

 Organization address address: Place De L'Universite 1
city: LOUVAIN LA NEUVE
postcode: 1348

contact info
Titolo: Ms.
Nome: Anne
Cognome: Bovy
Email: send email
Telefono: -473851
Fax: -474808

BE (LOUVAIN LA NEUVE) hostInstitution 1˙493˙320.00
2    UNIVERSITE CATHOLIQUE DE LOUVAIN

 Organization address address: Place De L'Universite 1
city: LOUVAIN LA NEUVE
postcode: 1348

contact info
Titolo: Prof.
Nome: Pierre
Cognome: Sonveaux
Email: send email
Telefono: -7645237
Fax: -7645239

BE (LOUVAIN LA NEUVE) hostInstitution 1˙493˙320.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

activation    critical    hypoxia    mct    lactate    hif    glycolytic    glycolysis    switch    cancers    angiogenesis    types    cancer   

 Obiettivo del progetto (Objective)

'Cancer lethality is most often associated to occurrence of distant metastases. To grow and become aggressive, cancers may undergo 2 critical adaptations: the glycolytic switch, corresponding to uncoupling glycolysis from the tricarboxylic acid (TCA) cycle, and the angiogenic switch, promoting neovascularization. In this high risk/high gain research program, we propose that the glycolytic switch precedes and promotes angiogenesis and metastatic dissemination in most types of cancer. We further envision that lactate, the end product of glycolysis, interfaces glycolysis and the latter processes through activation of hypoxia-inducible factor HIF-1. A thorough characterization of the molecular pathway(s) initiated by lactate (using transcriptomic, gene silencing, enzymatic and pharmacological interventions) has the potential to unravel new therapeutic targets that would simultaneously inhibit the consequences of the glycolytic switch on cancer aggressiveness. We anticipate the plasma membrane lactate transporters of the (sodium) monocarboxylate transporter (S)MCT family to be key determinants of autocrine and paracrine lactate signaling in cancer. Modulation of their activity or expression (notably by the generation of (S)MCT knock out mice) could thus profoundly affect tumor angiogenesis and metastasis. Since hypoxia is a hallmark of cancer and glycolysis its direct consequence in cancer cells surviving to hypoxia, the findings could have important consequences for the treatment of virtually all types of cancers. It could also impact our understanding of other pathologies, such as wound healing and heart infarction, in which the interplay between glycolysis, HIF-1 activation and angiogenesis could play a critical role.'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

POLPBAR (2010)

Production of Polarized Antiprotons

Read More  

NATREP (2012)

The nature of representation

Read More  

MALONCO (2014)

Targeting cancer using evolutionary refined pathogen derived antigens

Read More